Explore

Trendline Trendline
Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026
Trendline Trendline
Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy
Trendline Trendline
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Trendline Trendline
Avalyn Pharma Aims to Raise $300 Million in Upscaled IPO for Respiratory Therapies

Avalyn Pharma Aims to Raise $300 Million in Upscaled IPO for Respiratory Therapies

Avalyn Pharma Aims to Raise $300 Million in Upscaled IPO for Respiratory Therapies
Trendline Trendline
D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types
Trendline Trendline
AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment
Trendline Trendline
Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma
Trendline Trendline
AbbVie Reports Strong Q1 Earnings, Raises 2026 Outlook Amid Strategic Portfolio Adjustments

AbbVie Reports Strong Q1 Earnings, Raises 2026 Outlook Amid Strategic Portfolio Adjustments

AbbVie Reports Strong Q1 Earnings, Raises 2026 Outlook Amid Strategic Portfolio Adjustments
Trendline Trendline
AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal
Trendline Trendline
Erasca Reports Promising Preliminary Results in Cancer Therapy Trials

Erasca Reports Promising Preliminary Results in Cancer Therapy Trials

Erasca Reports Promising Preliminary Results in Cancer Therapy Trials
Trendline Trendline
Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility